ARTL Stock Forecast: Artelo Biosciences, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Artelo Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Value (10): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ARTL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ARTL, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2025 | Maxim Group | Downgrade | Hold | — |
| 8 Sept 2025 | D. Boral Capital | Downgrade | Hold | — |
| 26 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 July 2025 | D. Boral Capital | Upgrade | Buy | — |
| 11 June 2025 | D. Boral Capital | Downgrade | Hold | — |
| 6 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 2 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 9 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 9 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 1 Oct 2024 | EF Hutton | Initiates | Buy | $6.00 |
| 14 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
ARTL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ARTL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −404.0%
- Return on assets
- −111.6%
- Dividend yield
- —
Higher than 3% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Artelo Biosciences, Inc. has a market value of $1.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$12.7M.
Free cash flow in the twelve months to 30 June 2026: −$12.6M.
Artelo Biosciences, Inc. employs 7 people.
Data provided by Twelve Data
ARTL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ARTL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Artelo Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ARTL
How does Ticker Nerd's model rank ARTL?
As at 21 Nov 2026, Artelo Biosciences, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
What is the ARTL stock forecast for 2030?
No analyst covering Artelo Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARTL are extrapolating price history, which says nothing about the business.
What does Artelo Biosciences, Inc. do?
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways. Artelo Biosciences concentrates on treatments for conditions with significant unmet medical needs, including cancer-related anorexia, pain, inflammation, anxiety, dermatologic disorders, and other serious diseases.
About Artelo Biosciences, Inc.
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways. Artelo Biosciences concentrates on treatments for conditions with significant unmet medical needs, including cancer-related anorexia, pain, inflammation, anxiety, dermatologic disorders, and other serious diseases. Its current pipeline includes product candidates such as ART27.13, ART12.11, and ART26.12, which are being developed across multiple therapeutic areas with an emphasis on endocannabinoid and fatty acid binding protein biology. The company’s work centers on advancing novel small-molecule and cannabinoid-based approaches aimed at improving care in oncology, neurology, and related fields. Artelo Biosciences is headquartered in Solana Beach, California, and operates as a research-driven company within the broader pharmaceutical market.
CEO Mr. Gregory D. Gorgas M.B.A. · 7 employees · United States · https://artelobio.com